Efficacy and safety of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials. (2022). SKIN The Journal of Cutaneous Medicine, 6(6), s76. https://doi.org/10.25251/skin.6.supp.76